FEV1 reversibility does not adequately predict effect of formoterol via Aerolizer® in chronic obstructive pulmonary disease

International Journal of Clinical Practice

Volumn 58, Issue 5, 2004, Pages 457-464

  Muir, J F ^a   Benhamou, D ^a   Cuvelier, A ^a   Le Gros, V ^b   Overend, T ^c   Till, D ^c   Della Cioppa, Giovanni ^c   Kottakis, J ^d  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^b NOVARTIS PHARMA K K   (Japan)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

COPD; Formoterol; Reversibility

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG USE; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS;

EID: 2942718553     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00164.x     Document Type: Article

References (46)

1. Global initiative for chronic obstructive lung disease (GOLD). Global Strateg for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. National Institutes of Health, National Heart, Lung, and Blood Institute Publication Number 2701 updated March 2003.
2. Siafakas NM, Vermeire P, Pride NB et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-420.
3. British Thoracic Society. Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (Suppl. 5): S1-S30.
4. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive lung disease. Am J Respir Crit Care Med 1995; 152: S77-S120.
5. Canadian Respiratory Review Panel. Guidelines for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) 1998.
6. Société de Pneumologie de Langue Française. Recommandations pour la prise en charge des bronchopneumopathies chroniques obstructives. Rev Mal Respir 1997; 4: 2S1-2S92.
7. Anthonisen NR, Wright EC, IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 814-9.
8. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112: 336-40.
9. Boyd G, Morice AH, Pounsford JC et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-21.
10. Maesen BLP, Westermann CJJ, Duurkens VAM, van den Bosch JM. Effects of formoterol in apprarently poorly reversible chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 1103-8.
11. Kottakis I, Bouros D, Siafakas NM et al. Effects of formoterol and salmeterol on inspiratory capacity: results from a single dose, 5-period, cross-over study in stable, poorly reversible, stage II and III COPD patients. Am J Respir Crit Care Med 2001; 163: A278.
12. D'Urzo A, De Salvo MC, Ramirez-Rivera A et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001; 119: 1347-56.
13. Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65.
14. Dahl R, Greefhorst APM, Thomson MH et al. Formoterol (Foradil®) improves lung function and quality of life (QoL) parameters in patients with reversible and poorly reversible COPD. Am J Respir Crit Care Med 2001; 163: A280.
15. Kristufek P, Levine B, Till D et al. Inhaled formoterot (Foradil®) improves lung function in patients with both reversible and poorly reversible COPD. Am J Respir Crit Care Med 2001; 163: A280.
16. Cazzola M, Lorenzo G, Perna F et al. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 2000; 118: 1576-81.
17. Cook D, Guyatt G, Wong E et al. Regular versus as-needed short-acting inhaled β-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 85-90.
18. Van Noord JA, Bantje ThA, Eland ME et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55: 289-94.
19. Littner MR, Ilowite JS, Tashkin DP et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1136-42.
20. Rennard SI, Serby CW, Ghafouri M et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials. Chest 1996; 110: 62-70.
21. 1 improvement of 12% and 200 ml predictive of long-term improvements with bronchodilators in patients with COPD? Am J Respir Crit Care Med 2001; 163: A280.
22. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-92.
23. Dahl R, Greefhorst LAPM, Nowak D et al. Inhaled formoterol dry powder versus ipratropiurn bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-84.
24. Rossi A, Kristufck P, Levine BE et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-69.
25. Levine B, Till D, Byrne A. Formoterol improves lung function in patients with reversible chronic obstructive pulmonary disease. Chest 2001; 120: 252S.
26. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85 (Suppl. B): 25-31.
27. Cazzola M, Vinciguerra A, Di Perna F, Matera MG. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease. Respir Med 1998; 92: 1012-6.
28. Mahler DA. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002; 110 (6 Suppl.): S298-303.
29. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium. in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441-9.
30. Tantucci C, Duget A, Similowski T et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998; 12: 799-804.
31. Quadrelli SA, Roncoroni AJ, Porcel G. Analysis of variability in interpretation of spirometric tests. Respiration 1996; 63: 131-6.
32. Rodriquez-Carballeira M, Heredia JL, Rues M et al. The bronchodilator test with increasing doses of terbutaline in chronic obstructive pulmonary disease patients. Pulm Pharmacol Ther 2001; 14: 61-5.
33. Corsico A, Tinelli C, Zoia MC et al. The traditional bronchodilator test does not allow airway obstruction to be classified as reversible or irreversible in COPD patients. Am J Respir Crit Care Med 2001; 163: A695.
34. Hansen EF, Phanareth K, Laursen LC et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1267-71.
35. Rodriquez-Carballeira M, Heredia JL, Gomez L et al. Contribution of ipratropium bromide to the bronchodilator test in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 1999; 12: 43-8.
36. Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of ipratropiurn and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115: 966-71.
37. Dahl R, Greeffiorst APM, Nowak D et al. Onset of action of inhaled formoterol compared to ipatropiurn bromide in patients with COPD. Eur Respir J 2000; 13 (Suppl.): 52S.
38. Benhamou D, Cuvelier A, Muir JF et al. Rapid onset of bronchodilation in COPD. a placebo-controlled study comparing formoterol (Foradil® Aerolizer™) with salbutamol (Ventodisk™). Respir Med 2001; 95: 817-21.
39. 2-adrenoceptor agonist bronchodilator. Life Sci 1993; 52: 2145-60.
40. Santus P, Pecchiari M, Carlucci P et al. Bronchodilation test in COPD: effect of inspiratory manoeuvre preceding forced expiration. Eur Respir J 2003; 21: 82-5.
41. Anthonisen NR, Wright EC, IPPB Trial Groups. Response to inhaled bronchodilators in COPD. Chest 1987; 91 (Suppl.): 36S-39S.
42. Dow L. Asthma versus chronic obstructive pulmonary disease-exploring why 'reversibility versus irreversibility' is no longer an appropriate approach. Clin Exp Allergy 1999; 29: 739-43.
43. Quadrelli SA, Roncoroni AJ, Montiel GC. Evaluation of bronchodilator response in patients with airway obstruction. Respir Med 1999; 93: 630-6.
44. 1. Eur Respir J 1992; 5: 975-81.
45. Celli BR. The importance of spirometry in COPD and Asthma. Effect on approach to management. Chest 2000; 117 (Suppl.): 15S-19S.
46. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest 2000; 117 (Suppl.): 42S-47S.